These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36268559)

  • 1. The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.
    Steiro I; Vandsemb EN; Elsaadi S; Misund K; Sponaas AM; Børset M; Abdollahi P; Slørdahl TS
    Oncotarget; 2022 Oct; 13():1175-1186. PubMed ID: 36268559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase.
    Domoto T; Takino T; Guo L; Sato H
    Cancer Sci; 2012 Mar; 103(3):448-54. PubMed ID: 22118498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity.
    Szabo R; Hobson JP; List K; Molinolo A; Lin CY; Bugge TH
    J Biol Chem; 2008 Oct; 283(43):29495-504. PubMed ID: 18713750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model.
    Ye J; Kawaguchi M; Haruyama Y; Kanemaru A; Fukushima T; Yamamoto K; Lin CY; Kataoka H
    Cancer Sci; 2014 Jan; 105(1):44-51. PubMed ID: 24147538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase.
    Larsen BR; Steffensen SD; Nielsen NV; Friis S; Godiksen S; Bornholdt J; Soendergaard C; Nonboe AW; Andersen MN; Poulsen SS; Szabo R; Bugge TH; Lin CY; Skovbjerg H; Jensen JK; Vogel LK
    Exp Cell Res; 2013 Apr; 319(6):918-29. PubMed ID: 23333561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.
    Mitchell AC; Kannan D; Hunter SA; Parra Sperberg RA; Chang CH; Cochran JR
    J Biol Chem; 2018 Apr; 293(14):4969-4980. PubMed ID: 29386351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of an active zymogen protease: the zymogen form of matriptase is regulated by HAI-1 and HAI-2.
    Skovbjerg S; Holt-Danborg L; Nonboe AW; Hong Z; Frost ÁK; Schar CR; Thomas CC; Vitved L; Jensen JK; Vogel LK
    Biochem J; 2020 May; 477(9):1779-1794. PubMed ID: 32338287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasin.
    Friis S; Sales KU; Schafer JM; Vogel LK; Kataoka H; Bugge TH
    J Biol Chem; 2014 Aug; 289(32):22319-32. PubMed ID: 24962579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
    Oberst M; Anders J; Xie B; Singh B; Ossandon M; Johnson M; Dickson RB; Lin CY
    Am J Pathol; 2001 Apr; 158(4):1301-11. PubMed ID: 11290548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
    Chou FP; Chen YW; Zhao XF; Xu-Monette ZY; Young KH; Gartenhaus RB; Wang JK; Kataoka H; Zuo AH; Barndt RJ; Johnson M; Lin CY
    Am J Pathol; 2013 Oct; 183(4):1306-17. PubMed ID: 24070417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.
    Kohama K; Kawaguchi M; Fukushima T; Lin CY; Kataoka H
    Hum Cell; 2012 Dec; 25(4):100-10. PubMed ID: 23248048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.
    Zhao B; Yuan C; Li R; Qu D; Huang M; Ngo JC
    J Biol Chem; 2013 Apr; 288(16):11155-64. PubMed ID: 23443661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness.
    Baba T; Kawaguchi M; Fukushima T; Sato Y; Orikawa H; Yorita K; Tanaka H; Lin CY; Sakoda S; Kataoka H
    J Pathol; 2012 Oct; 228(2):181-92. PubMed ID: 22262311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
    Kanemaru A; Yamamoto K; Kawaguchi M; Fukushima T; Lin CY; Johnson MD; Camerer E; Kataoka H
    Int J Cancer; 2017 Jan; 140(1):130-141. PubMed ID: 27615543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation.
    Chen YW; Wang JK; Chou FP; Chen CY; Rorke EA; Chen LM; Chai KX; Eckert RL; Johnson MD; Lin CY
    J Biol Chem; 2010 Oct; 285(41):31755-62. PubMed ID: 20696767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.
    Wang JK; Lee MS; Tseng IC; Chou FP; Chen YW; Fulton A; Lee HS; Chen CJ; Johnson MD; Lin CY
    Am J Physiol Cell Physiol; 2009 Aug; 297(2):C459-70. PubMed ID: 19535514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
    Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
    Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.
    Tseng IC; Chou FP; Su SF; Oberst M; Madayiputhiya N; Lee MS; Wang JK; Sloane DE; Johnson M; Lin CY
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C423-31. PubMed ID: 18550704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.
    Xu H; Xu Z; Tseng IC; Chou FP; Chen YW; Wang JK; Johnson MD; Kataoka H; Lin CY
    Am J Physiol Cell Physiol; 2012 Jan; 302(2):C453-62. PubMed ID: 22031598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.